繁体
简体
Company news IP granted Publications
2026-07-20
Risen Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
Details
Year:
All 2026 2025 2024 2023 2022 2021 2020
2026-07-20
Risen Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
Detail
2025-05-06
Risen Pharma Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Detail
2024-12-23
Congratulations to Risen for being listed on the "Hurun Global Cheetahs Index 2024"
Detail
2024-12-09
Congratulations to Risen and its chairman Jiasheng Lv, Ph.D. for being listed on the （Baoding International Medical Base · Hurun China Healthcare Pioneering Young Start-ups 2024）and（Baoding International Medical Base ·
Detail
2024-11-13
PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.
Detail
2024-11-13
Risen Pharma and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.
Detail
上一页 1 2 3 下一页
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
Jiangsu Xuzhou R&D Center
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb